Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INDUSTRY-SPONSORED DEVICE-SPECIFIC BIOMATERIALS ADVISORY PANELS PROPOSED BY FDA SCIENCE BOARD MEMBER; AGENCY CITES CONFLICT-OF-INTEREST CONCERNS

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers of devices incorporating new biomaterials should be able to convene ad hoc advisory panels to help FDA address regulatory issues unique to the materials, FDA Science Board member Pedro Cuatrecasas, MD, president of pharmaceutical research at Parke-Davis, proposed at the board's meeting Nov. 6 in Arlington, Virginia.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel